MARTINSRIED (dpa-AFX) - MediGene AG (MDGEF.PK) said it continues clinical development of its drug candidate RhuDex by initiating a clinical formulation study. The purpose of the trial is to develop an optimized oral formulation of the active substance suitable for treating chronic diseases. RhuDex is a CD80 antagonist that blocks the undesired activation and proliferation of T cells and thus has an immunomodulating and anti-inflammatory effect. According to Dr. Frank Mathias, chief executive officer of MediGene, 'The initiation of this formulation study is an important step in the development of this innovative drug candidate. We developed an optimized formulation concept which, in the case of successful clinical testing, will add a significant competitive advantage to RhuDex.' The results of the formulation study are expected by middle of 2012.
Copyright RTT News/dpa-AFX
© 2012 AFX News
